Latigo Biotherapeutics

News

BlossomHill, VogenX and Latigo reveal IPO plans

Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, VogenX, and Latigo - as 2026 heads for a record IPO haul.

News

Latigo raises $150m for non-opioid painkiller push

Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.

News

Freenome raises $254m for cancer tests, and other financings

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien

BlossomHill, VogenX and Latigo reveal IPO plans

Latigo raises $150m for non-opioid painkiller push

Freenome raises $254m for cancer tests, and other financings

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks